

PSJ17 Exh 19



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville MD 20857

NOV 4 1998

NDA*20-747

NOV 4 1998

Anesta Corporation
4745 Wiley Post Way, Suite 650
Salt Lake City, Utah 84116

Attention: Patricia J. Richards
Director, Regulatory Affairs

Dear Ms. Richards:

Please refer to your new drug application (NDA) dated November 11, 1996, received November 13, 1996, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Actiq (oral transmucosal fentanyl citrate) 200, 400, 600, 800, 1200, and 1600 µg (fentanyl base).

We acknowledge receipt of your submissions dated April 30, July 29, September 4 and 22, October 9, 19, 29 and 30, and November 4, 1998. Your submission of April 30, 1998 constituted a complete response to our November 13, 1997 action letter. The user fee goal date is November 4, 1998.

This new drug application provides for the use of Actiq for the management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

We have reviewed this application under the restricted distribution regulations contained in 21 CFR 314.520 (Subpart H) and have concluded that restrictions on distribution and use of Actiq are needed to assure safe use of the product.

We have completed the review of this application, including the Actiq Risk Management Program (RMP) as amended. We have concluded that adequate information has now been presented to demonstrate that Actiq is safe and effective, when marketed in accordance with the terms of restricted distribution and use described in the Risk Management Program (attached to this letter), and as recommended in the attached final labeling text to which you agreed on November 4, 1998 in a telephone conversation between representatives of Anesta and of FDA.

PERSONAL AND CONFIDENTIAL
NOT FOR DISTRIBUTION

NOV 4 1998

NDA 20-747

Page 2

Accordingly, under the provisions of 21 CFR 314.520, this application is approved effective on the date of this letter.

CHANGES TO THE ACTIQ RISK MANAGEMENT PROGRAM:

Please note that the attached Risk Management Program (RMP) is an integral part of the approved NDA for this product and is an essential component of the terms of this NDA's approval by FDA for marketing this product in the United States. As such, any proposed change(s) in the Risk Management Program must be submitted to FDA as a supplement to the NDA and any proposed change must have FDA prior approval before implementation. Changing the Risk Management Program without prior FDA approval may render the product misbranded and an unapproved new drug.

FUTURE INSPECTIONS:

In order to monitor the success of compliance with the restricted distribution provisions of this approval action, we intend to conduct inspections of Anesta Corporation's and Abbott Laboratories' records during the first or second quarter after launch. We will meet with you to discuss the inspections within one month after completion of the inspections. Inspections and meetings with you will continue periodically thereafter as appropriate.

SPECIAL ADVERSE EVENT REPORTING REQUIREMENT of the RISK MANAGEMENT PROGRAM:

Please note that, until further notice, you are required to report the following types of adverse events to the FDA within 15 calendar days (as "15 Day Alert Reports") of your receipt of the report:

- Any unintended pediatric exposure (<16 years of age), whether or not there is a serious outcome and whether or not the outcome was unexpected
- Any serious adverse drug experience which is determined to occur in the context of diversion (i.e., use by an individual other than for whom it was prescribed), whether or not the experience is unexpected
- Any serious adverse drug experience that is determined to occur in the context of "off

NDA 20-747

Page 3

label use” (i.e., that is used outside of the approved indication for Actiq), whether or not the experience is unexpected.

Definitions of the above terms are as stated in 21 CFR 314.80. These special safety reporting requirements are in addition to the routine requirements for reporting of post-marketing adverse experience data established in 21 CFR 314.80.

FINAL PRINTED LABELING (including Professional Package Insert and Patient Package Insert):

The final printed labeling (FPL) must be identical to the attached approved final labeling text, including boxes, bolding, bullets, and other formatting provisions. Marketing the product with FPL that is not identical to this approved text may render the product misbranded and an unapproved new drug.

Please submit twenty copies of the FPL as soon as it is available, in no case more than thirty days after it is printed. Please individually mount ten copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated “FINAL PRINTED LABELING” for approved NDA 20-747. Approval of this submission by FDA is not required before the labeling is used.

PHASE FOUR COMMITMENTS:

Please be reminded of your Phase 4 commitments, specified in your submission dated November 4, 1998. These commitments, along with any completion dates agreed upon are listed below:

1. OUTREACH EDUCATION FOR RURAL AREAS

An educational outreach program will be designed within the first two months of Actiq approval. It will be implemented within the first year. The elements of this program which will need FDA review and approval will provide for education of pharmacists, health care professionals, and patients in rural areas that are not part of the initial target group.

2. STUDIES IN PEDIATRIC PATIENTS

A program to study appropriate dosing paradigms and safety profile in opiate-tolerant pediatric cancer patients with breakthrough cancer pain which will lead to informed prescribing instructions in the label—addressing appropriate starting dose, titration schedule, and safety at labeled doses—will be conducted. Patients will be dosed in a

NDA 20-747

Page 4

manner similar to the conditions defined in the Actiq prescribing information (modified as needed based on PK and tolerance). Safety under these conditions will be assessed with modifications based on pharmacokinetics and tolerance. The program will be designed to obtain specific safety information in the dosage range studied in pediatric patients. A secondary analysis of additional risk to families with other children in the home and a plan for managing that risk including an evaluation of the role of antagonist therapy will be submitted. Concurrence will be reached with FDA on the final design of this program. This program will be completed within the first two years after approval. Please note that this does not constitute a "Written Request" under Section 111 of FDAMA (Food and Drug Administration Modernization Act of 1997). If you are interested in pursuing activities described in Section 111, we will be happy to work with you on that.

3. STUDY IN HIV-INFECTED PATIENTS

The study of breakthrough pain in opiate-tolerant chronic pain patients with HIV infection may include HIV-infected patients with and without malignancy. Patients will be titrated and dosed in accordance with the Actiq prescribing information. Adverse experience data will be evaluated for qualitative differences in the adverse experience profile. Gross differences in the frequency of common opioid side effects as compared with the prescribing information will be sought. Particular attention will be paid to possible clinical manifestations of drug-drug interactions with antiviral drugs and other drugs used frequently in this patient population. Concurrence will be reached with FDA on the final design of this program. This program will be completed within the first two years after approval.

Protocols, data, and final reports should be submitted to your IND for this product and a copy of the cover letter sent to this NDA. If an IND is not required to meet your Phase 4 commitments, please submit protocols, data and final reports to this NDA as correspondence. In addition, under 21 CFR 314.81(b)(2)(vii), we request that you include a status summary of each commitment in your annual report to this NDA. The status summary should include the number of patients entered in each study, expected completion and submission dates, and any changes in plans since the last annual report. For administrative purposes, all submissions, including labeling supplements, relating to these Phase 4 commitments must be clearly designated "Phase 4 Commitments."

PROMOTIONAL ACTIVITIES:

Please note that promotional activities for this approved NDA are subject to 21 CFR 314.550. As such, please submit three copies of the introductory promotional materials that you

NDA 20-747

Page 5

propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional material and the final printed labeling or approved final labeling text to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
HFD-40
5600 Fishers Lane
Rockville, Maryland 20857

In addition, please note that this product has been approved **ONLY** for the management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

As such, please note that promotional statements or representations by you that this product may indeed be safe and efficacious in the treatment of diseases or patient populations beyond that contained in your approved labeling may be considered a violation of the Act. If you have any questions or concerns about this matter, please contact the Center for Drug Evaluation and Research's Division of Drug Marketing, Advertising, and Communications.

CHEMISTRY:

Validation of the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

Please submit one market package of the drug product when it is available.


NDA 20-747

Page 6

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80, 314.81, 314.520, 314.550, and 314.560.

If you have any questions, contact Nancy Chamberlin, Project Manager, at (301) 827-7410.

Sincerely,

A handwritten signature in black ink that reads "Cynthia McCormick MD". The signature is fluid and cursive, with the "MD" written in a slightly different style than the name.

Cynthia McCormick, MD

Director

Division of Anesthetic, Critical Care, and Addiction

Drug Products, HFD-170

Office of Drug Evaluation III

Center for Drug Evaluation and Research

Enclosure:

Labeling

Risk Management Program